» Articles » PMID: 28166811

Pathogenic Variant Burden in the ExAC Database: an Empirical Approach to Evaluating Population Data for Clinical Variant Interpretation

Overview
Journal Genome Med
Publisher Biomed Central
Specialty Genetics
Date 2017 Feb 8
PMID 28166811
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The frequency of a variant in the general population is a key criterion used in the clinical interpretation of sequence variants. With certain exceptions, such as founder mutations, the rarity of a variant is a prerequisite for pathogenicity. However, defining the threshold at which a variant should be considered "too common" is challenging and therefore diagnostic laboratories have typically set conservative allele frequency thresholds.

Methods: Recent publications of large population sequencing data, such as the Exome Aggregation Consortium (ExAC) database, provide an opportunity to characterize with accuracy and precision the frequency distributions of very rare disease-causing alleles. Allele frequencies of pathogenic variants in ClinVar, as well as variants expected to be pathogenic through the nonsense-mediated decay (NMD) pathway, were analyzed to study the burden of pathogenic variants in 79 genes of clinical importance.

Results: Of 1364 BRCA1 and BRCA2 variants that are well characterized as pathogenic or that are expected to lead to NMD, 1350 variants had an allele frequency of less than 0.0025%. The remaining 14 variants were previously published founder mutations. Importantly, we observed no difference in the distributions of pathogenic variants expected to be lead to NMD compared to those that are not. Therefore, we expanded the analysis to examine the distributions of NMD expected variants in 77 additional genes. These 77 genes were selected to represent a broad set of clinical areas, modes of inheritance, and penetrance. Among these variants, most (97.3%) had an allele frequency of less than 0.01%. Furthermore, pathogenic variants with allele frequencies greater than 0.01% were well characterized in publications and included many founder mutations.

Conclusions: The observations made in this study suggest that, with certain caveats, a very low allele frequency threshold can be adopted to more accurately interpret sequence variants.

Citing Articles

Structural and functional insights into α-actinin isoforms and their implications in cardiovascular disease.

Noureddine M, Mikolajek H, Morgan N, Denning C, Loughna S, Gehmlich K J Gen Physiol. 2025; 157(2).

PMID: 39918740 PMC: 11804879. DOI: 10.1085/jgp.202413684.


Interpreting Variants of Uncertain Significance in PCD: Abnormal Splicing Caused by a Missense Variant of DNAAF3.

Zheng H, Cheng C, He M, Zhou W, Li Y, Dai J Mol Genet Genomic Med. 2025; 13(1):e70036.

PMID: 39764684 PMC: 11705539. DOI: 10.1002/mgg3.70036.


Actionable Variants of Unknown Significance in Inherited Arrhythmogenic Syndromes: A Further Step Forward in Genetic Diagnosis.

Martinez-Barrios E, Greco A, Cruzalegui J, Cesar S, Diez-Escute N, Cerralbo P Biomedicines. 2024; 12(11).

PMID: 39595119 PMC: 11591737. DOI: 10.3390/biomedicines12112553.


Clinical Variant Reclassification in Hereditary Disease Genetic Testing.

Kobayashi Y, Chen E, Facio F, Metz H, Poll S, Swartzlander D JAMA Netw Open. 2024; 7(11):e2444526.

PMID: 39504018 PMC: 11541632. DOI: 10.1001/jamanetworkopen.2024.44526.


Interpreting the actionable clinical role of rare variants associated with short QT syndrome.

Martinez-Barrios E, Greco A, Cruzalegui J, Cesar S, Diez-Escute N, Cerralbo P Hum Genet. 2024; 143(12):1499-1508.

PMID: 39503779 PMC: 11576798. DOI: 10.1007/s00439-024-02713-x.


References
1.
Petrovski S, Wang Q, Heinzen E, Allen A, Goldstein D . Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 2013; 9(8):e1003709. PMC: 3749936. DOI: 10.1371/journal.pgen.1003709. View

2.
Gao F, Keinan A . High burden of private mutations due to explosive human population growth and purifying selection. BMC Genomics. 2014; 15 Suppl 4:S3. PMC: 4083409. DOI: 10.1186/1471-2164-15-S4-S3. View

3.
Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P . Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract. 2016; 14:5. PMC: 4739084. DOI: 10.1186/s13053-016-0046-5. View

4.
Janavicius R, Rudaitis V, Mickys U, Elsakov P, Griskevicius L . Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet. 2014; 207(5):195-205. DOI: 10.1016/j.cancergen.2014.05.002. View

5.
Daly M, Pilarski R, Axilbund J, Berry M, Buys S, Crawford B . Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016; 14(2):153-62. DOI: 10.6004/jnccn.2016.0018. View